Negative regulation of the inflammasome: Keeping inflammation under control

Immunological Reviews

Volumn 265, Issue 1, 2015, Pages 231-257

  Pedraza Alva, Gustavo ^a   Pérez Martínez, Leonor ^a   Valdez Hernández, Laura ^a   Meza Sosa, Karla F ^a   Ando Kuri, Masami ^a  

^a INSTITUTO DE BIOTECNOLOGÍA   (Mexico)

Author keywords

NLRP; Caspase 1; IL 18; IL 1 ; Inflammasome; Inflammation

Indexed keywords

ALOE VERA EXTRACT; ARSENIC ACID DERIVATIVE; ARTEMISIA ANNUA EXTRACT; CARD ONLY PROTEIN; CHAPERONE; GINSENG EXTRACT; GLIBENCLAMIDE; GREEN TEA EXTRACT; HEAT SHOCK PROTEIN; IMMUNOGLOBULIN G; INFLAMMASOME; MICRORNA; OMEGA 3 FATTY ACID; POLYENYLPYRROLE DERIVATIVE; PROPOLIS; PROTEIN HIN200; PYD ONLY PROTEIN; PYRIN; PYRROLE DERIVATIVE; THROMBOMODULIN; UNCLASSIFIED DRUG; VINEGAR; INTERLEUKIN 18; INTERLEUKIN 1BETA;

ADAPTIVE IMMUNITY; ALOE VERA; APOPTOSIS; ARTEMISIA ANNUA; AUTOPHAGY; BAMBOO; CELL CYCLE REGULATION; CHLAMYDIA TRACHOMATIS; DNA DAMAGE; FRANCISELLA TULARENSIS; GINSENG; HUMAN; INFLAMMATION; INNATE IMMUNITY; INSULIN SENSITIVITY; LEGIONELLA PNEUMOPHILA; MOLECULAR INTERACTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PSEUDOMONAS AERUGINOSA; RED WINE; REGULATORY MECHANISM; REVIEW; SALMONELLA; SECOND MESSENGER; SHIGELLA FLEXNERI; TEA; UBIQUITINATION; VIBRIO; YERSINIA PESTIS; ANIMAL; HOMEOSTASIS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM;

ANIMALS; HOMEOSTASIS; HUMANS; IMMUNE TOLERANCE; INFLAMMASOMES; INFLAMMATION; INTERLEUKIN-18; INTERLEUKIN-1BETA;

EID: 84927779737     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12294     Document Type: Review

References (197)

1. Alnemri ES, et al. Human ICE/CED-3 protease nomenclature. Cell 1996;87:171.
2. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002;10:417-426.
3. Montero Laura V-H, Pérez-Lemus C, Pedraza-Alva G. Inflammasomes: Homeostasis guardians in Molecular Aspects of Inflammation. In: Pérez-Martínez L, Pedraza-Alva G, Osorio EF eds. Kerala, India: Research Signpost, 2013.
4. Miao EA, et al. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat Immunol 2010;11:1136-1142.
5. Abdul-Sater AA, et al. Inflammasome-dependent caspase-1 activation in cervical epithelial cells stimulates growth of the intracellular pathogen Chlamydia trachomatis. J Biol Chem 2009;284:26789-26796.
6. Yilmaz O, et al. ATP-dependent activation of an inflammasome in primary gingival epithelial cells infected by Porphyromonas gingivalis. Cell Microbiol 2010;12:188-198.
7. de Rivero Vaccari JP, et al. P2X4 receptors influence inflammasome activation after spinal cord injury. J Neurosci 2012;32:3058-3066.
8. Oslowski CM, et al. Thioredoxin-interacting protein mediates ER stress-induced beta cell death through initiation of the inflammasome. Cell Metab 2012;16:265-273.
9. Naik E, Dixit VM. Modulation of inflammasome activity for the treatment of auto-inflammatory disorders. J Clin Immunol 2010;30:485-490.
10. Druilhe A, et al. Regulation of IL-1beta generation by Pseudo-ICE and ICEBERG, two dominant negative caspase recruitment domain proteins. Cell Death Differ 2001;8:649-657.
11. Lamkanfi M, et al. INCA, a novel human caspase recruitment domain protein that inhibits interleukin-1beta generation. J Biol Chem 2004;279:51729-51738.
12. Saleh M, et al. Enhanced bacterial clearance and sepsis resistance in caspase-12-deficient mice. Nature 2006;440:1064-1068.
13. Saleh M, et al. Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature 2004;429:75-79.
14. Rosenstiel P, et al. A short isoform of NOD2/CARD15, NOD2-S, is an endogenous inhibitor of NOD2/receptor-interacting protein kinase 2-induced signaling pathways. Proc Natl Acad Sci USA 2006;103:3280-3285.
15. Stehlik C, et al. The PAAD/PYRIN-only protein POP1/ASC2 is a modulator of ASC-mediated nuclear-factor-kappa B and pro-caspase-1 regulation. Biochem J 2003;373(Pt 1):101-113.
16. Bruey JM, et al. Bcl-2 and Bcl-XL regulate proinflammatory caspase-1 activation by interaction with NALP1. Cell 2007;129:45-56.
17. Cheng X, Kao HY. Post-translational modifications of PML: consequences and implications. Front Oncol 2012;2:210.
18. Dowling JK, et al. Promyelocytic leukemia protein (PML) interacts with ASC to limit inflammasome activation. J Biol Chem 2014;289:6429-6437.
19. Jin J, et al. LRRFIP2 negatively regulates NLRP3 inflammasome activation in macrophages by promoting Flightless-I-mediated caspase-1 inhibition. Nat Commun 2013;4:2075.
20. Roberts TL, et al. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science 2009;323:1057-1060.
21. Yin Q, et al. Molecular mechanism for p202-mediated specific inhibition of AIM2 inflammasome activation. Cell Rep 2013;4:327-339.
22. Kaminski JJ, et al. Synthetic oligodeoxynucleotides containing suppressive TTAGGG motifs inhibit AIM2 inflammasome activation. J Immunol 2013;191:3876-3883.
23. Cheng X, et al. Suppressive oligodeoxynucleotides inhibit atherosclerosis in ApoE(-/-) mice through modulation of Th1/Th2 balance. J Mol Cell Cardiol 2008;45:168-175.
24. Sato T, et al. Suppressive oligodeoxynucleotides inhibit silica-induced pulmonary inflammation. J Immunol 2008;180:7648-7654.
25. Shirota H, et al. Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock. J Immunol 2005;174:4579-4583.
26. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 2012;367:2015-2025.
27. Fann DY, et al. Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke. Cell Death Dis 2013;4:e790.
28. Shi CS, et al. Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood 2008;112:3661-3670.
29. Conway EM, et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 2002;196:565-577.
30. Abeyama K, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005;115:1267-1274.
31. Van de Wouwer M, et al. The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost 2006;4:1813-1824.
32. Yang SM, et al. Thrombomodulin domain 1 ameliorates diabetic nephropathy in mice via anti-NF-kappaB/NLRP3 inflammasome-mediated inflammation, enhancement of NRF2 antioxidant activity and inhibition of apoptosis. Diabetologia 2014;57:424-434.
33. Wagner RN, et al. Evaluation of Nod-like receptor (NLR) effector domain interactions. PLoS ONE 2009;4:e4931.
34. Wen H, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 2011;12:408-415.
35. Toye AA, et al. A genetic and physiological study of impaired glucose homeostasis control in C57BL/6J mice. Diabetologia 2005;48:675-686.
36. Martin BN, et al. IKKalpha negatively regulates ASC-dependent inflammasome activation. Nat Commun 2014;5:4977.
37. Lawrence T, et al. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 2005;434:1138-1143.
38. Xiao Z, et al. The pivotal role of IKKalpha in the development of spontaneous lung squamous cell carcinomas. Cancer Cell 2013;23:527-540.
39. Hara H, et al. Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity. Nat Immunol 2013;14:1247-1255.
40. Hernandez-Cuellar E, et al. Cutting edge: nitric oxide inhibits the NLRP3 inflammasome. J Immunol 2012;189:5113-5117.
41. Mayer-Barber KD, et al. Innate and adaptive interferons suppress IL-1alpha and IL-1beta production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity 2011;35:1023-1034.
42. Toda N, Okamura T. Role of nitric oxide in neurally induced cerebroarterial relaxation. J Pharmacol Exp Ther 1991;258:1027-1032.
43. Guarda G, et al. T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. Nature 2009;460:269-273.
44. + memory T-cells indirectly inhibit NLRP3 inflammasome activation through downregulation of P2X7R signalling. PLoS ONE 2012;7:e39576.
45. Guarda G, et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011;34:213-223.
46. Pockley AG. Heat shock proteins as regulators of the immune response. Lancet 2003;362:469-476.
47. Ferat-Osorio E, et al. Heat shock protein 70 down-regulates the production of toll-like receptor-induced pro-inflammatory cytokines by a heat shock factor-1/constitutive heat shock element-binding factor-dependent mechanism. J Inflamm (Lond) 2014;11:19.
48. Azevedo C, et al. The RAR1 interactor SGT1, an essential component of R gene-triggered disease resistance. Science 2002;295:2073-2076.
49. Mayor A, et al. A crucial function of SGT1 and HSP90 in inflammasome activity links mammalian and plant innate immune responses. Nat Immunol 2007;8:497-503.
50. Py BF, et al. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol Cell 2013;49:331-338.
51. Giguere PM, et al. G Protein signaling modulator-3 inhibits the inflammasome activity of NLRP3. J Biol Chem 2014;289:33245-33257.
52. Levin TC, et al. Heat shock inhibits caspase-1 activity while also preventing its inflammasome-mediated activation by anthrax lethal toxin. Cell Microbiol 2008;10:2434-2446.
53. Deretic V. Autophagy in immunity and cell-autonomous defense against intracellular microbes. Immunol Rev 2011;240:92-104.
54. Harris J. Autophagy and IL-1 family cytokines. Front Immunol 2013;4:83.
55. Harris J, et al. T helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium tuberculosis. Immunity 2007;27:505-517.
56. Saitoh T, et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 2008;456:264-268.
57. Harris J, et al. Autophagy controls IL-1beta secretion by targeting pro-IL-1beta for degradation. J Biol Chem 2011;286:9587-9597.
58. Nakahira K, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 2011;12:222-230.
59. Hu Y, et al. Tripartite-motif protein 30 negatively regulates NLRP3 inflammasome activation by modulating reactive oxygen species production. J Immunol 2010;185:7699-7705.
60. Chuang SY, et al. TLR-induced PAI-2 expression suppresses IL-1beta processing via increasing autophagy and NLRP3 degradation. Proc Natl Acad Sci USA 2013;110:16079-16084.
61. Shi CS, et al. Activation of autophagy by inflammatory signals limits IL-1beta production by targeting ubiquitinated inflammasomes for destruction. Nat Immunol 2012;13:255-263.
62. Bodemann BO, et al. RalB and the exocyst mediate the cellular starvation response by direct activation of autophagosome assembly. Cell 2011;144:253-267.
63. Bicker S, Schratt G. microRNAs: tiny regulators of synapse function in development and disease. J Cell Mol Med 2008;12:1466-1476.
64. Cao X, et al. Noncoding RNAs in the mammalian central nervous system. Annu Rev Neurosci 2006;29:77-103.
65. Fiore R, Siegel G, Schratt G. MicroRNA function in neuronal development, plasticity and disease. Biochim Biophys Acta 2008;1779:471-478.
66. Klein ME, et al. Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. Nat Neurosci 2007;10:1513-1514.
67. Meza-Sosa KF, et al. Role of microRNAs in central nervous system development and pathology. J Neurosci Res 2012;90:1-12.
68. Olsen PH, Ambros V. The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. Dev Biol 1999;216:671-680.
69. Zhao Y, Srivastava D. A developmental view of microRNA function. Trends Biochem Sci 2007;32:189-197.
70. Li X, Jin P. Roles of small regulatory RNAs in determining neuronal identity. Nat Rev Neurosci 2010;11:329-338.
71. Dai R, Ahmed SA. MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Transl Res 2011;157:163-179.
72. Glinsky GV. SNP-guided microRNA maps (MirMaps) of 16 common human disorders identify a clinically accessible therapy reversing transcriptional aberrations of nuclear import and inflammasome pathways. Cell Cycle 2008;7:3564-3576.
73. Dai R, et al. Suppression of LPS-induced interferon-gamma and nitric oxide in splenic lymphocytes by select estrogen-regulated microRNAs: a novel mechanism of immune modulation. Blood 2008;112:4591-4597.
74. Bauernfeind F, et al. NLRP3 inflammasome activity is negatively controlled by miR-223. J Immunol 2012;189:4175-4181.
75. Ohlsson L, et al. Aluminium based adjuvants and their effects on mitochondria and lysosomes of phagocytosing cells. J Inorg Biochem 2013;128:229-236.
76. Guo H, et al. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010;466:835-840.
77. Bandyopadhyay S, et al. MicroRNA-133a-1 regulates inflammasome activation through uncoupling protein-2. Biochem Biophys Res Commun 2013;439:407-412.
78. BasuBall W, et al. Uncoupling protein 2 negatively regulates mitochondrial reactive oxygen species generation and induces phosphatase-mediated anti-inflammatory response in experimental visceral leishmaniasis. J Immunol 2011;187:1322-1332.
79. Tacke F, et al. Levels of circulating miR-133a are elevated in sepsis and predict mortality in critically ill patients. Crit Care Med 2014;42:1096-1104.
80. Chartoumpekis DV, et al. Differential expression of microRNAs in adipose tissue after long-term high-fat diet-induced obesity in mice. PLoS ONE 2012;7:e34872.
81. Ortega FJ, et al. Targeting the circulating microRNA signature of obesity. Clin Chem 2013;59:781-792.
82. Vandanmagsar B, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011;17:179-188.
83. Zampetaki A, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010;107:810-817.
84. Kameswaran V, et al. Epigenetic regulation of the DLK1-MEG3 microRNA cluster in human type 2 diabetic islets. Cell Metab 2014;19:135-145.
85. Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999;26:259-265.
86. Yan Y, et al. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity 2013;38:1154-1163.
87. Zhou R, et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010;11:136-140.
88. Pacheco Rodrigo C. Cells, Molecules and Mechanisms Involved in the Neuro-Immune Interaction, in Cell Interaction. Gowder S, ed. Rijeka, Croatia: InTech, 2012.
89. Kobayashi H, et al. Human eosinophils produce neurotrophins and secrete nerve growth factor on immunologic stimuli. Blood 2002;99:2214-2220.
90. Pavlov VA, et al. The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation. Mol Med 2003;9:125-134.
91. Rosas-Ballina M, et al. The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE. Mol Med 2009;15:195-202.
92. Sun Y, et al. Stress-induced corticotropin-releasing hormone-mediated NLRP6 inflammasome inhibition and transmissible enteritis in mice. Gastroenterology 2013;144:1478-1487, 1487 e1-8.
93. 2+ and cAMP. Nature 2012;492:123-127.
94. Chang CP, et al. Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron 1993;11:1187-1195.
95. Elinav E, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011;145:745-757.
96. Farooq A, et al. Activation of N-methyl-d-aspartate receptor downregulates inflammasome activity and liver inflammation via a beta-arrestin-2 pathway. Am J Physiol Gastrointest Liver Physiol 2014;307:G732-G740.
97. Feng B, et al. Metabolic profiling analysis of a D-galactosamine/lipopolysaccharide-induced mouse model of fulminant hepatic failure. J Proteome Res 2007;6:2161-2167.
98. Habib P, Beyer C. Regulation of brain microglia by female gonadal steroids. J Steroid Biochem Mol Biol 2014;146:3-14.
99. Ray CA, et al. Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme. Cell 1992;69:597-604.
100. Garcia-Calvo M, et al. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem 1998;273:32608-32613.
101. Zhou Q, et al. Target protease specificity of the viral serpin CrmA. Analysis of five caspases. J Biol Chem 1997;272:7797-7800.
102. Kettle S, et al. Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1beta-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever. J Gen Virol 1997;78(Pt 3):677-685.
103. Petit F, et al. Characterization of a myxoma virus-encoded serpin-like protein with activity against interleukin-1 beta-converting enzyme. J Virol 1996;70:5860-5866.
104. Turner SJ, et al. Characterization of the ectromelia virus serpin, SPI-2. J Gen Virol 2000;81(Pt 10):2425-2430.
105. Rahman MM, McFadden G. Myxoma virus lacking the pyrin-like protein M013 is sensed in human myeloid cells by both NLRP3 and multiple Toll-like receptors, which independently activate the inflammasome and NF-kappaB innate response pathways. J Virol 2011;85:12505-12517.
106. Johnston JB, Rahman MM, McFadden G. Strategies that modulate inflammasomes: insights from host-pathogen interactions. Semin Immunopathol 2007;29:261-274.
107. Dorfleutner A, et al. A Shope Fibroma virus PYRIN-only protein modulates the host immune response. Virus Genes 2007;35:685-694.
108. Gonzalez JM, Esteban M. A poxvirus Bcl-2-like gene family involved in regulation of host immune response: sequence similarity and evolutionary history. Virol J 2010;7:59.
109. Bahar MW, et al. How vaccinia virus has evolved to subvert the host immune response. J Struct Biol 2011;175:127-134.
110. Gerlic M, et al. Vaccinia virus F1L protein promotes virulence by inhibiting inflammasome activation. Proc Natl Acad Sci USA 2013;110:7808-7813.
111. Gregory SM, et al. Discovery of a viral NLR homolog that inhibits the inflammasome. Science 2011;331:330-334.
112. Orzalli MH, DeLuca NA, Knipe DM. Nuclear IFI16 induction of IRF-3 signaling during herpesviral infection and degradation of IFI16 by the viral ICP0 protein. Proc Natl Acad Sci USA 2012;109:E3008-E3017.
113. Johnson KE, Chikoti L, Chandran B. Herpes simplex virus 1 infection induces activation and subsequent inhibition of the IFI16 and NLRP3 inflammasomes. J Virol 2013;87:5005-5018.
114. Pelegrin P, Surprenant A. Dynamics of macrophage polarization reveal new mechanism to inhibit IL-1beta release through pyrophosphates. EMBO J 2009;28:2114-2127.
115. Komune N, et al. Measles virus V protein inhibits NLRP3 inflammasome-mediated interleukin-1beta secretion. J Virol 2011;85:13019-13026.
116. Niebler M, et al. Post-translational control of IL-1beta via the human papillomavirus type 16 E6 oncoprotein: a novel mechanism of innate immune escape mediated by the E3-ubiquitin ligase E6-AP and p53. PLoS Pathog 2013;9:e1003536.
117. Haneklaus M, et al. Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1beta production. J Immunol 2012;189:3795-3799.
118. Jorgensen I, et al. The Chlamydia protease CPAF regulates host and bacterial proteins to maintain pathogen vacuole integrity and promote virulence. Cell Host Microbe 2011;10:21-32.
119. Rajaram MV, et al. Akt/Protein kinase B modulates macrophage inflammatory response to Francisella infection and confers a survival advantage in mice. J Immunol 2006;177:6317-6324.
120. Ulland TK, et al. Cutting edge: mutation of Francisella tularensis mviN leads to increased macrophage absent in melanoma 2 inflammasome activation and a loss of virulence. J Immunol 2010;185:2670-2674.
121. Huang MT, et al. Deletion of ripA alleviates suppression of the inflammasome and MAPK by Francisella tularensis. J Immunol 2010;185:5476-5485.
122. Ge J, et al. Preventing bacterial DNA release and absent in melanoma 2 inflammasome activation by a Legionella effector functioning in membrane trafficking. Proc Natl Acad Sci USA 2012;109:6193-6198.
123. Creasey EA, Isberg RR. The protein SdhA maintains the integrity of the Legionella-containing vacuole. Proc Natl Acad Sci USA 2012;109:3481-3486.
124. Boyden ED, Dietrich WF. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat Genet 2006;38:240-244.
125. Banga S, et al. Legionella pneumophila inhibits macrophage apoptosis by targeting pro-death members of the Bcl2 protein family. Proc Natl Acad Sci USA 2007;104:5121-5126.
126. Yamada H, et al. Protective role of interleukin-1 in mycobacterial infection in IL-1 alpha/beta double-knockout mice. Lab Invest 2000;80:759-767.
127. Mayer-Barber KD, et al. Caspase-1 independent IL-1beta production is critical for host resistance to Mycobacterium tuberculosis and does not require TLR signaling in vivo. J Immunol 2010;184:3326-3330.
128. Walter K, et al. NALP3 is not necessary for early protection against experimental tuberculosis. Immunobiology 2010;215:804-811.
129. Saiga H, et al. Critical role of AIM2 in Mycobacterium tuberculosis infection. Int Immunol 2012;24:637-644.
130. Mishra BB, et al. Mycobacterium tuberculosis protein ESAT-6 is a potent activator of the NLRP3/ASC inflammasome. Cell Microbiol 2010;12:1046-1063.
131. Shah S, et al. Cutting edge: Mycobacterium tuberculosis but not nonvirulent mycobacteria inhibits IFN-beta and AIM2 inflammasome-dependent IL-1beta production via its ESX-1 secretion system. J Immunol 2013;191:3514-3518.
132. Franchi L, et al. Critical role for Ipaf in Pseudomonas aeruginosa-induced caspase-1 activation. Eur J Immunol 2007;37:3030-3039.
133. Sutterwala FS, et al. Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome. J Exp Med 2007;204:3235-3245.
134. Barbieri JT, Sun J. Pseudomonas aeruginosa ExoS and ExoT. Rev Physiol Biochem Pharmacol 2004;152:79-92.
135. Gross O, et al. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature 2009;459:433-436.
136. Roy S, Karmakar M, Pearlman E. CD14 mediates Toll-like receptor 4 (TLR4) endocytosis and spleen tyrosine kinase (Syk) and interferon regulatory transcription factor 3 (IRF3) activation in epithelial cells and impairs neutrophil infiltration and Pseudomonas aeruginosa killing in vivo. J Biol Chem 2014;289:1174-1182.
137. Rodriguez M, et al. Polarization of the innate immune response by prostaglandin E2: a puzzle of receptors and signals. Mol Pharmacol 2014;85:187-197.
138. Raupach B, et al. Caspase-1-mediated activation of interleukin-1beta (IL-1beta) and IL-18 contributes to innate immune defenses against Salmonella enterica serovar Typhimurium infection. Infect Immun 2006;74:4922-4926.
139. Fink SL, Cookson BT. Pyroptosis and host cell death responses during Salmonella infection. Cell Microbiol 2007;9:2562-2570.
140. Castro-Eguiluz D, et al. B cell precursors are targets for Salmonella infection. Microb Pathog 2009;47:52-56.
141. Perez-Lopez A, et al. Salmonella downregulates Nod-like receptor family CARD domain containing protein 4 expression to promote its survival in B cells by preventing inflammasome activation and cell death. J Immunol 2013;190:1201-1209.
142. Suzuki T, et al. Differential regulation of caspase-1 activation, pyroptosis, and autophagy via Ipaf and ASC in Shigella-infected macrophages. PLoS Pathog 2007;3:e111.
143. Kobayashi T, et al. The Shigella OspC3 effector inhibits caspase-4, antagonizes inflammatory cell death, and promotes epithelial infection. Cell Host Microbe 2013;13:570-583.
144. Haines GK 3rd, et al. Role of toll-like receptor 4 in the proinflammatory response to Vibrio cholerae O1 El tor strains deficient in production of cholera toxin and accessory toxins. Infect Immun 2005;73:6157-6164.
145. Toma C, et al. Pathogenic Vibrio activate NLRP3 inflammasome via cytotoxins and TLR/nucleotide-binding oligomerization domain-mediated NF-kappa B signaling. J Immunol 2010;184:5287-5297.
146. Higa N, et al. Vibrio parahaemolyticus effector proteins suppress inflammasome activation by interfering with host autophagy signaling. PLoS Pathog 2013;9:e1003142.
147. Brodsky IE, et al. A Yersinia effector protein promotes virulence by preventing inflammasome recognition of the type III secretion system. Cell Host Microbe 2010;7:376-387.
148. Orth K, et al. Inhibition of the mitogen-activated protein kinase kinase superfamily by a Yersinia effector. Science 1999;285:1920-1923.
149. Schesser K, et al. The yopJ locus is required for Yersinia-mediated inhibition of NF-kappaB activation and cytokine expression: YopJ contains a eukaryotic SH2-like domain that is essential for its repressive activity. Mol Microbiol 1998;28:1067-1079.
150. Boland A, Cornelis GR. Role of YopP in suppression of tumor necrosis factor alpha release by macrophages during Yersinia infection. Infect Immun 1998;66:1878-1884.
151. Ruckdeschel K, et al. Yersinia enterocolitica impairs activation of transcription factor NF-kappaB: involvement in the induction of programmed cell death and in the suppression of the macrophage tumor necrosis factor alpha production. J Exp Med 1998;187:1069-1079.
152. Schotte P, et al. Targeting Rac1 by the Yersinia effector protein YopE inhibits caspase-1-mediated maturation and release of interleukin-1beta. J Biol Chem 2004;279:25134-25142.
153. LaRock CN, Cookson BT. The Yersinia virulence effector YopM binds caspase-1 to arrest inflammasome assembly and processing. Cell Host Microbe 2012;12:799-805.
154. Oliviero F, et al. Epigallocatechin-3-gallate reduces inflammation induced by calcium pyrophosphate crystals in vitro. Front Pharmacol 2013;4:51.
155. Melgarejo E, et al. Targeting of histamine producing cells by EGCG: a green dart against inflammation? J Physiol Biochem 2010;66:265-270.
156. Shin HY, et al. Epigallocatechin-3-gallate inhibits secretion of TNF-alpha, IL-6 and IL-8 through the attenuation of ERK and NF-kappaB in HMC-1 cells. Int Arch Allergy Immunol 2007;142:335-344.
157. Ichikawa D, et al. Effect of various catechins on the IL-12p40 production by murine peritoneal macrophages and a macrophage cell line, J774.1. Biol Pharm Bull 2004;27:1353-1358.
158. Ahmed S, et al. Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1 beta-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. Free Radic Biol Med 2002;33:1097-1105.
159. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009;27:519-550.
160. Tsai PY, et al. Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation. Free Radic Biol Med 2011;51:744-754.
161. Ellis LZ, et al. Green tea polyphenol epigallocatechin-3-gallate suppresses melanoma growth by inhibiting inflammasome and IL-1beta secretion. Biochem Biophys Res Commun 2011;414:551-556.
162. Yu CS, et al. Aloe-emodin affects the levels of cytokines and functions of leukocytes from Sprague-Dawley rats. In Vivo 2006;20:505-509.
163. Budai MM, et al. Aloe vera downregulates LPS-induced inflammatory cytokine production and expression of NLRP3 inflammasome in human macrophages. Mol Immunol 2013;56:471-479.
164. Panee J. Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes. Cytokine 2012;60:1-12.
165. Higa JK, Panee J. Bamboo extract reduces interleukin 6 (IL-6) overproduction under lipotoxic conditions through inhibiting the activation of NF-kappaB and AP-1 pathways. Cytokine 2011;55:18-23.
166. Ho CL, et al. Bamboo vinegar decreases inflammatory mediator expression and NLRP3 inflammasome activation by inhibiting reactive oxygen species generation and protein kinase C-alpha/delta activation. PLoS ONE 2013;8:e75738.
167. Hua KF, et al. Polyenylpyrrole derivatives inhibit NLRP3 inflammasome activation and inflammatory mediator expression by reducing reactive oxygen species production and mitogen-activated protein kinase activation. PLoS ONE 2013;8:e76754.
168. Hu QH, et al. Allopurinol, quercetin and rutin ameliorate renal NLRP3 inflammasome activation and lipid accumulation in fructose-fed rats. Biochem Pharmacol 2012;84:113-125.
169. Xiong Z, et al. Artemisinin, an anti-malarial agent, inhibits rat cardiac hypertrophy via inhibition of NF-kappaB signaling. Eur J Pharmacol 2010;649:277-284.
170. Wang Y, et al. The anti-malarial artemisinin inhibits pro-inflammatory cytokines via the NF-kappaB canonical signaling pathway in PMA-induced THP-1 monocytes. Int J Mol Med 2011;27:233-241.
171. Zhu C, et al. Artemisinin attenuates lipopolysaccharide-stimulated proinflammatory responses by inhibiting NF-kappaB pathway in microglia cells. PLoS ONE 2012;7:e35125.
172. Gu Y, et al. Artemisinin attenuates post-infarct myocardial remodeling by down-regulating the NF-kappaB pathway. Tohoku J Exp Med 2012;227:161-170.
173. Wu X, et al. Therapeutic effect of artemisinin on lupus nephritis mice and its mechanisms. Acta Biochim Biophys Sin (Shanghai) 2010;42:916-923.
174. Wang Z, et al. Anti-inflammatory properties and regulatory mechanism of a novel derivative of artemisinin in experimental autoimmune encephalomyelitis. J Immunol 2007;179:5958-5965.
175. Shi JQ, et al. Antimalarial drug artemisinin extenuates amyloidogenesis and neuroinflammation in APPswe/PS1dE9 transgenic mice via inhibition of nuclear factor-kappaB and NLRP3 inflammasome activation. CNS Neurosci Ther 2013;19:262-268.
176. Lu JM, Yao Q, Chen C. Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol 2009;7:293-302.
177. Kang S, Min H. Ginseng, the 'immunity boost': the effects of panax ginseng on immune system. J Ginseng Res 2012;36:354-368.
178. Kim J, et al. Korean red ginseng extracts inhibit NLRP3 and AIM2 inflammasome activation. Immunol Lett 2014;158:143-150.
179. Paulino N, et al. Anti-inflammatory effects of a bioavailable compound, Artepillin C, in Brazilian propolis. Eur J Pharmacol 2008;587:296-301.
180. de Sousa JP, et al. A reliable quantitative method for the analysis of phenolic compounds in Brazilian propolis by reverse phase high performance liquid chromatography. J Sep Sci 2007;30:2656-2665.
181. Bankova V. Chemical diversity of propolis and the problem of standardization. J Ethnopharmacol 2005;10:114-117.
182. Salatino A, et al. Origin and chemical variation of Brazilian propolis. Evid Based Complement Alternat Med 2005;2:33-38.
183. Hori JI, et al. The inhibition of inflammasome by Brazilian propolis (EPP-AF). Evid Based Complement Alternat Med 2013;2013:418508.
184. Nurmi K, et al. Ethanol inhibits activation of NLRP3 and AIM2 inflammasomes in human macrophages - a novel anti-inflammatory action of alcohol. PLoS ONE 2013;8:e78537.
185. Lo YH, et al. Selective inhibition of the NLRP3 inflammasome by targeting to promyelocytic leukemia protein in mouse and human. Blood 2013;121:3185-3194.
186. Maier NK, et al. Arsenic trioxide and other arsenical compounds inhibit the NLRP1, NLRP3, and NAIP5/NLRC4 inflammasomes. J Immunol 2014;192:763-770.
187. Hamon Y, et al. Interleukin-1beta secretion is impaired by inhibitors of the Atp binding cassette transporter, ABC1. Blood 1997;90:2911-2915.
188. Riddle MC. Editorial: sulfonylureas differ in effects on ischemic preconditioning - is it time to retire glyburide? J Clin Endocrinol Metab 2003;88:528-530.
189. Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest 2005;115:2047-2058.
190. Lamkanfi M, et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol 2009;187:61-70.
191. Fritsche K. Fatty acids as modulators of the immune response. Annu Rev Nutr 2006;26:45-73.
192. Zhang MJ, Spite M. Resolvins: anti-inflammatory and proresolving mediators derived from omega-3 polyunsaturated fatty acids. Annu Rev Nutr 2012;32:203-227.
193. Oh DY, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010;142:687-698.
194. Endres S, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989;320:265-271.
195. Hirasawa A, et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 2005;11:90-94.
196. Shin S, et al. The omega-3 polyunsaturated fatty acid DHA induces simultaneous apoptosis and autophagy via mitochondrial ROS-mediated Akt-mTOR signaling in prostate cancer cells expressing mutant p53. Biomed Res Int 2013;2013:568671.
197. Williams-Bey Y, et al. Omega-3 free fatty acids suppress macrophage inflammasome activation by inhibiting NF-kappaB activation and enhancing autophagy. PLoS ONE 2014;9:e97957.